Friday, March 1, 2019

Hematology Analyzers Market Key Manufacturers, Development Trends And Competitive Analysis 2026

Global Hematology Analyzers Market: Overview
The demand within the global market for hematology analyzers has been escalating on account of the rising incidence of diseases related to the blood. Hematology technology is only a nascent development in the field of healthcare but has come a long way in its usage and utility. Hematology analyzers are used to analyse blood samples by getting the count of white blood cells and conducting a reticulocyte analysis. Furthermore, coagulation tests are also an important function within healthcare that can be effectuated with the help of hematology analyzers. These analyzers are automated systems that are specialised to count the number of red cells, platelets, haemoglobin levels, and hematocrit levels. Due to such a wide expanse of operation for these analyzers, the demand for these products is expected to keep escalating in the forthcoming years. It is also worthwhile to state that the global diagnostic industry has also been expanding at a plush rate in recent times, which is also expected to enhance the growth prospects of the global market for hematology analyzers. Owing to the aforementioned factors, the global market for hematology analyzers is projected to attract key investment from several key stakeholders.
The global market for hematology analyzers is segmented on the basis of the following parameters: modality, end-user, product, and region. In order to understand the various dynamics of market growth, it is integral to delve into the specifics of the aforementioned segments.
A report added by Transparency Market Research (TMR) on the global market for hematology analyzers builds on several key parameters that have aided market growth in recent times. Furthermore, the report also projects the key trends that could accelerated the growth of the global market in the years to come.
Global Hematology Analyzers Market: Trends and Opportunities
The demand within the global hematology analyzers market has been rising on account of several key advancements in the field of diagnosis and testing. Several efforts to revolutionise the domain of blood testing have been made in the past, and the emergence of hematology analysers is the latest development in this domain. Hence, it is evident that the global market for hematology analyzers would expand at a starry rate in the years to come and would also give a launch pad to the growth of the global market players. Furthermore, the 3D approach to analysing hematology has also emerged as a key development that is projected to overhaul the growth prospects of the global market for hematology analyzer.
The methods of cellular analysis and advent of new software-capabilities are projected to enhance the growth prospects of the market for haematological analyzers. However, despite the pros that are driving demand, several researchers believe that these analyzers have reached the final stage of their product lifestyle and are a financial burden for the vendors. This factor could have a negative impact on the growth of the global market for hematology analyzers.
Global Hematology Analyzers Market: Regional Analysis
The demand within the hematology analyzers market in North America is expected to witness several key opportunities over the forthcoming years. It is expected that a paradigm shift would come to the fore of the regional market as better diagnostics are developed in the US and Canada.
Global Hematology Analyzers Market: Competitive Landscape
Some of the key players in the global hematology analyzers market are Abbott Laboratories, Mindray, Beckman Coulter Inc., and Edan Instruments, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Posted by at No comments:
Labels:

Single-Cell Genome Sequencing Market Size, Application Analysis, Regional Outlook, 2018-2026

Single-cell genome sequencing involves isolating a single cell and amplifying and sequencing genes within that single cell. Single-cell genome sequencing is a technique that is used to study the sequence data obtained through next-generation sequencing of a single cell. This method has come up as a strong tool that provides deep insights on genetics by analysis of the genomes at a cellular level. Single-cell genome sequencing technique has a great impact on different fields of biology comprising, cancer research, immunology microbiology, and neurobiology. Sequencing a single cell carries significant importance as individual cells can differ at great extent in size, protein levels, and expressed RNA transcripts. These variations could provide important insights about several research applications such as cancer research, stem cell biology, immunology, developmental biology, and neurology. Single-cell analysis enables a closer view of the gene expression of individual cells to understand their functions in complex tissues.
The global single-cell genome sequencing market has witnessed tremendous advances in the past five years and is expected to grow at a much faster pace in the coming future. This can be attributed due to rising incidence of chronic diseases such as cancer and diabetes and high prevalence rate of autoimmune disorders, growing R&D activities, and increasing focus on the key companies on product expansion are amongst the key developments propelling the market expansion. Also, favorable government policies and proper funding schemes are projected to propel the development of the global single-cell genome sequencing market in the coming years. Technological developments in the division of single-cell genome sequencing are likely to play an active role in the expansion of the global single-cell genome sequencing market. The technologically developed platforms offer perceptive analysis software solutions and are cost efficient in nature. For instance, genetic mosaicism is an area that is beginning to be studied at higher resolution using single-cell genome sequencing. Initial studies have begun to resolve intra-tumor heterogeneity, which has provided new biological insights into tumor formation
The global single-cell genome sequencing market can be segmented based on technology, indication, workflow, application, and end-user. Based on technology, the global single-cell genome sequencing market can be divided into multiple annealing and looping-based amplification cycles (MALBAC), multiple displacement amplification (MDA), and others. Based on the indication, the global single-cell genome sequencing market is categorized into cancer, rare diseases, immunological disorders, neurological disorders, and others. On the basis of workflow, the global single-cell genome sequencing market is categorized into sample preparation, single cell isolation, and genomic analysis. In terms of application, the global single-cell genome sequencing market is categorized into microbiome studies, genomic variation, automated cell capture, cell differentiation, and reprogramming, subpopulation characterization, and others. Based on end-user, the global single-cell genome sequencing market is divided into academic and research laboratories, clinics, biotechnology and biopharmaceutical companies, and others. Single-cell genomics is providing front-line clinical applications, especially in the genetic diagnosis of pre-implantation human embryos followed by In-vitro fertilization techniques.
On the basis of geography, the global single-cell genome sequencing market can be divided among North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the market leader in single-cell genome sequencing market followed by Europe. The U.S. is the most important revenue contributor in North America due to its rising prevalence of immunological and oncological disorders, and increasing cases of rare diseases. Also, continued innovation and technological advancement by key players in the region is also adding up to the growth of the single-cell genome sequencing market in North America. Europe is also witnessing high growth in the single-cell genome sequencing market attributed to the increased laboratory and clinical research in the European countries. On the other hand, Asia Pacific has emerged as the fastest growing division due to rising R&D expenditure in the countries like China & India. Furthermore, ample administration collaborations and support among entities are also projected to propel the expansion of the Asian single-cell genomics market.
Some of the most important market players in the global single-cell genome sequencing market are F Hoffmann-La Roche Ltd., 10x Genomics, Bio-Rad Laboratories, Fluidigm, Novogene, Illumina, Inc., BGI, Pacific Biosciences, Oxford Nanopore Technologies, QIAGEN, and Thermo Fisher Scientific, Inc., among others.
Posted by at No comments:
Labels:

Cell Based Assays Market is Projected to be Worth US$ 19,710.7 Mn by 2022

Global Cell Based Assays Market: Snapshot
The demand in the global cell based assays market is expanding at a CAGR of 7.7% during the forecast period of 2017 to 2022, gaining traction from a number of factors such as prevalence of numerous chronic diseases, government support for the research and development activities, and improving healthcare infrastructure in emerging economies in Asia Pacific. On the other hand, restrictions on the usage of reagents and high cost of instruments are the factors that are challenging the prosperity of the global cell based assays market. In terms of revenue, the global cell based assays market is estimated to be worth US$19,710.7 mn by 2022, significantly up from its evaluated valuation of US$13,576.7 mn in 2017.Global Cell Based Assays Market.jpgReagents and Consumables Emerges As Profitable Product Segment
Based on product type, the global cell based assays market has been segmented into instruments, reagents and consumables, assay kits, services, and software. Among these, reagents and consumables constituted 32.1% of the overall demand for cell based assays in 2017, which was worth US$4,356.6 mn. Increasing adoption of cell-based consumables by prominent biopharmaceutical companies and growing number of contact research organizations are some of the factors reflecting positively on this segment. By the end of the forecast period, 2022, the reagents and consumables segment is expected to lose a little bit of ground, although it will remain the most profitable product-type, promising a demand worth of US$6,260.2 mn by 2022. This segment alone is projected for a CAGR of 7.5% during the said forecast period.
On the basis of end-user, the global cell based assays market has been bifurcated into pharmaceutical and biotechnology companies, academic institutions, contract research organizations, and other end-users such as clinical laboratories, hospitals, and environmental monitoring labs. Currently, pharmaceutical and biotechnology companies serve the maximum demand, which is a reflection of growing adoption of cell-based assays for drug discovery by the end users, especially in the developed countries within North America and Europe. Application-wise, the global cell based assays market has been categorized into drug discovery, predictive toxicology, basic research, and other applications.
North America to Remain Most Profitable Region Until 2022
Geographically, this report gauges the potential of cell based assays market in the regions of Europe, North America, Asia Pacific except Japan (APEJ), Latin America, and the Middle East and Africa (MEA), as well as in the country of Japan. In 2017, North America emerged as the most lucrative region for the vendors operating in this market, representing a demand worth of US$5,164.0 mn. The North America cell based assays market has been expected to experience incrementing demand at an above-average CAGR of 8.2% to reach a valuation of US$7,672.5 mn by 2022. The dominance of this region can be attributed to growing availability of funds for research and resilient drug discovery activities in the country of the U.S. While Europe is currently the second most profitable region, promising a demand for cell based assays that would be worth US$4,864.3 mn by 2022, its CAGR for the said forecast period is 6.9%, substantially lower than the same for APEJ, which is projected to increment the demand at 8.1%. China and India are identified as most profitable countries in the region of Asia Pacific except Japan, driven by the availability of low cost labor, which has attracted a number of companies to invest.
Presence of Numerous Players Making Competitive Landscape Fragmented
Some of the key companies currently operating in the global cell based assays market are: Becton, Dickinson and Company, GE Healthcare, Cell Signaling Technology, Life Technologies Corporation, Danahar Corporation, Cisbio Bioassays, Merck KGaA, Discoverx Corporation, Thermo Fisher Scientific Inc., Perkinelmer Inc., Promega Corporation, Proqinase GmbH, Enzo Life Sciences, Inc., Charles River Laboratories International, Inc., Biospherix, Ltd., Essen Bioscience, Marine Biological Laboratory, Miltenyi Biotec, Bioagilytix Labs., Lonza, Aurelia Bioscience Ltd., Selexis SA, Cell Biolabs, Inc., Biotek Instruments, Inc., Qgel SA.
Posted by at No comments:
Labels:

Viral Inactivation Market to Report a CAGR of 7.4% Between 2017 and 2025

Global Viral Inactivation Market: Snapshot
A popular strategy with savvy players in the global market for viral inactivation trying to bolster their positions is the thrust on acquisitions. Besides, they are also investing heavily in research and development to come up with new products in response to various requirements for treating diseases. A dominant players in the market, namely Merck & Co., Inc., is seen to have a stronghold across nations worldwide.
At the forefront of driving growth in the global market for viral inactivation is the rising approvals of new drugs, rules pertaining to viral safety of biologics, and the proliferation of the biologics and biosimilars industry. Besides, the growing instances of various infectious diseases and growing application of biosimilars therapeutic treatment for a range of diseases are also positively impacting the market.
Proving counterproductive to the market, on the downside, is the high costs involved in developing and manufacturing biologics and biosimilars products and also the high price of equipment for viral inactivation. However, new types of viruses needing vaccinations to be developed against them spells new opportunities for the market.
A report by Transparency Market Research predicts the global viral inactivation market to expand at a healthy 7.4% CAGR from 2017 to 2025 to become worth US$5.736 bn by 2025 from US$3.05 bn in 2016.
Effectiveness of Chemical Method Drives it to Fore Vis-à-vis Market Share
Depending upon the type of method, the global viral inactivation market can be divided segmented into chemical, radiation, and others such as pasteurization and dry and moist heat treatment. Of them, the chemical method leads the market with maximum share as it is a robust and effective method of inactivation of different types of viruses. It is also cost-effective, safe, and brings about a high degree of purity of sample. The chemical method is further sub-segmented into solvent detergent method, use of alkylating agent method, and pH concentration method. The solvent detergent method, among them, is projected to account for largest market share by the end of 2025.
In terms of growth rate, however, the radiation method for viral inactivation is expected to outpace all others on account of the rising adoption of the method in blood centers in developed nations. The UV radiation method has been tested and developed for viral inactivation of blood and blood components at blood centers and at commercial manufacturing facilities.
Robust Biopharmaceutical Industry Makes North America Dominant Region
From a geographical standpoint, North America currently holds a sway over the global market on account of a robust biopharmaceutical industry, swift uptake of newer viral inactivation methodologies, rising demand for blood and blood components for transfusion therapy, and strict regulatory guidelines for the viral safety of biologics products. By growing at a CAGR of 7.2% in the forecast period, the market will likely become worth US$2.31 bn by 2025.
However, North America is slated to lose some of its market share to Asia Pacific, which is predicted to expand at maximum pace. The report by TMR projects the viral inactivation market in the region to clock a CAGR of 7.9% from 2017 to 2025. The region’s growth will be primarily powered by countries of South Korea, Japan, and Australia which have strict rules in place for purity of biologics and biosimilars products and also by China, India, and Malaysia having a booming biopharmaceutical industry.
Some of the dominant players in the global market for viral inactivation are Shandong Weigao Group Medical Polymer Company Limited, Sartorius AG, Cerus Corporation, Macopharma SA, and Terumo BCT, Inc.

Posted by at No comments:
Labels:

Pacemaker Devices Market is Projected to Soar at a Value CAGR of 8.1% from 2017 to 2022

Global Pacemaker Device Market: Snapshot
The global market for pacemaker devices is expected to witness significant growth owing to the increasing expansion of medical equipment industry. The growth has also been increasing due to the advancements in cardiac treatment devices made by governing authorities. With the frequent mishaps in cardiovascular conditions especially in Western Economies, is anticipated to grow the pacemaker devices market steadily in the forecast period. Many companies have also started to focus on business expansion and innovation so as to persist intense competition over emerging markets. The technological innovations have made the use of pacemakers more convenient and this has resulted in enhancing the growth of global pacemaker devices market throughout the forecast period.
According to the report published by TMR, the pacemaker devices market was valued at US$5.5 billion in the year 2017 and is anticipated to be worth US$8.1 billion by the end of 2022. The global market exhibits a robust CAGR of 8.1% in the forecast period 2017-2022.
The Global Pacemaker Devices Market to be dominated by Implantable Pacemaker Devices
According to product, the pacemaker devices market is bifurcated into implantable and external pacemaker. Among these, implantable pacemaker is expected to lead the market from 2017 to 2022 as it covered over 65% of the overall market in the year 2017. The continuous development in product innovation and increasing demand for advanced pacemaker devices is responsible for the growth of implantable pacemaker devices segment. In addition to this, implantable pacemaker devices are more accurate in readings and convenient for patients than external ones, thus enabling it to be the most preferred segment throughout the forecast period.
According to end-use, the global pacemaker devices market is divided into cardiac clinics, hospitals, and ambulant surgical centers. The hospitals are witnessing an increase in the number of patients which is expected to make hospitals the leading end-user of pacemaker devices market. This is coupled with the need for surgical procedures and physical assessment before grafting the pacemaker.
North America to Lead the Global Market for Pacemaker Devices Owing to the Presence of Key Players and Various Medical Institutes
As per regions, the global market for pacemaker devices is spread over Asia Pacific, North America, Europe, and Middle East & Africa. North America, as per revenue generation dominated the market globally. In the year 2017, the market in North America earned a revenue of US$1921.6 million. This is expected to increase to US$2917.9 million by the end of 2022. The overall pacemaker devices market in North America is likely to highlight a CAGR of 8.7% during the forecast period. Owing to rising growth of these devices in this region, together with existence of various medical organizations and global key players, North America is holding a strong growth in the market for pacemaker devices.
Europe as well has been a main contributor in the pacemaker devices market. This region is expected to cover around 25% of the market share in the forecast period. Also, Asia Pacific excluding Japan is anticipated to lead the regional pacemaker devices market in the years to come. The main reason for the growth in this region is due to the increasing cardiac arrests. The Asia pacific market except Japan is estimated to grow at a value worth US$1692.2 million by the end of 2022. The region is likely to exhibit a CAGR of 8.3% from 2017-2022.
The global market for pacemaker devices is established with the presence of numerous medical companies. The market is estimated to be more intense in competition as the number of specialist leaders have increased in the global market. Few of the prominent leaders operating in the pacemaker devices market globally include Medtronic Plc., Lepu Medical Technology, Pacetronix Limited, Abbott Laboratories, Zoll Medical Corpo, Boston Scientific Corp., Biotronik SE & Co. KG, OSYPKA AG, and Oscor Inc. among others.
Posted by at No comments:
Labels:

Bioprocess Technology Market is Projected to Soar at a Value CAGR of 8.5% from 2018 to 2026

Global Bioprocess Technology Market – Snapshot
Bioprocess is defined as a technique that is used to produce biological materials such as genetic microbial strains and commercially useful chemicals through biological processes. Increase in interest in areas of life science such as pharmacology & toxicology, biotechnology, etc. for the development of advanced medicines and vaccines has created the need for advanced bioprocess technology. Applications of bioprocess technology include antibiotics, recombinant proteins, biosimilars, cell culture, cellular analysis, etc.. Based on product, the global bioprocess technology market has been classified into instruments segment and consumables & accessories segment. The global bioprocess technology market was valued at over US$ 20 Bn in 2017 and is anticipated to expand at a CAGR of around 9.0 % from 2018 to 2026 to reach around US$ 44 Bn by 2026.

Report Overview @ https://www.transparencymarketresearch.com/bioprocess-technology-market.html

Expansion in the biopharmaceutical industry is anticipated to boost the bioprocess technology market. The global biopharma sector continued its positive momentum in 2017. With annual sales of over US$ 200 Bn and industry revenue growing in double digits, the future looks promising for this sector. Sustained patient demand for innovative drugs is expected to continue to play a key role in the growth of the biopharma sector. The bioprocess technology market is being positively impacted by rise in flexibility in terms of customization. Easy availability of customized single-use bags and bioreactors/fermenters has led to increased demand for them from end-users.

Demand for bioprocess technology has increased from both greenfield facilities as well as brown field facilities due to advancements in technology and the momentum is likely to continue. Thus, innovations in product offerings are likely to boost sales of bioprocess technology equipment. For instance, in June 2015, Merck Millipore introduced the Mobius 2000 liter single-use bioreactor, which featured the industry’s first pull-out drawer and self-deploying bag, thereby making assembly installation and inflation safe and easy. Increased demand for vaccine development and increased prevalence rate of several acute and chronic diseases is also driving demand for bioprocess technology.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19445

The global bioprocess technology market is in the growth stage. Major players such as F. Hoffmann-La Roche Ltd, Sartorius Group, Thermo Fisher Scientific, Inc., and Danaher have strong presence in the global bioprocess technology market. In the past few years, the global bioprocess technology market has witnessed high investments by various multinational manufacturers such as Nova Biomedical, Siemens Healthineers and Becton, and Dickinson and Company. The global market is driven by increase in demand for vaccines, expansion in the biopharmaceutical industry, and rise in number of new drug launches. For example, in July 2016, Advanced Instruments introduced OsmoPRO, which is able to analyze several types of samples, such as, blood, urine, cell culture, biological cell, etc.. In February 2018, Advanced Instruments launched Osmo 1 Single Sample Micro-Osmometer, which is expected to increase efficiency, decrease sample turnaround time, and reduce the risk of loss of sample.

The global bioprocess technology market has been segmented based on product, application, end-user, and region. In terms of product, the market has been classified into instruments and consumables & accessories. The consumables & accessories segment leads the market and is expected to continue to dominate the market during the forecast period. High rate of adoption of cell culture media globally for several research and development studies is driving the segment. Bioreactors was a major sub-segment of the instruments segment in 2017. The culture media sub-segment of the consumables & accessories segment is estimated to expand at a significant CAGR in the coming years. In terms of application, the recombinant proteins segment is expected to expand at a rapid CAGR from 2018 to 2026. Recombinant proteins was a leading segment in 2017 and is likely to account for a major market share during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19445
North America constituted a dominant share of the global bioprocess technology market in 2017. The predominance of the bioprocessing technology market in the U.S. over that in in Canada in 2017 is owing to the high sales of biopharmaceutical products, higher number of academic and research organizations, and higher number of biopharmaceutical manufacturing plants in the U.S.. The market share of Asia Pacific is projected to rise during the forecast period. The region is likely to be significant in terms of revenue in the next few years. Development of health care infrastructure; rise in population; growth of the biotechnology industry; and increase in burden of diseases necessitating diagnostics in Brazil, South Africa, Saudi Arabia, etc. are likely to fuel the market in Latin America and Middle East & Africa.

Key companies operating in the global bioprocess technology market and profiled in the report include F. Hoffmann-La Roche Ltd, Sartorius Group, Thermo Fisher Scientific, Inc., and Danaher. These players are adopting advanced techniques in the development of bioprocess technology to expand product offerings, strengthen geographical reach, increase customer base, and garner market share. In March 2018, Sartorius Group introduced ambr 250 HT perfusion system for cell culture process development at the BPI West 2018 Conference in San Francisco, U.S.. In April 2015, F. Hoffmann-La Roche Ltd., introduced Cedex bioprocess analyzer for vaccine manufacturing.

Posted by at No comments:
Labels:

Brain Tumor Diagnosis and Treatments Market Opportunity will Rise to US$ 840.7 Mn by 2025

Global Brain Tumor Diagnosis and Treatments Market: Snapshot
The demand in the global market for brain tumor diagnosis and treatments is anticipated to increase at a potent CAGR of 8.5% during the forecast period of 2017 to 2025. The prosperity of this market is primarily a reflection of innovations in drug delivery to brain cancer cells, increasing prevalence of brain cancer, rising aging population, and growing incidences of cancer via chemical exposure. On the other hand, exponentially high cost of diagnostic as well as treatment is the most prominent hindrance over this market. The global for brain tumor diagnosis and treatments market was worth US$406.0 mn in 2016, and is estimated to reach a valuation of US$840.7 mn by the end of the forecast period, which is 2025.
CT-Scan Remains High-Demand Diagnosis Segment
Based on product-type, the global brain tumor diagnosis and treatments market has been segmented into primary brain tumor and secondary brain tumor. The primary brain tumor segment, which accounted for 74.7% of the overall demand in 2016, has been sub-segmented into common tumors such as meningioma, astrocytomas, gliomas, and pituitary tumors. Along all sub-segments, meningioma continues to be most prevalent across the world, including Asia Pacific and Europe. It has been observed that in these two regions, CNS and brain tumors are the third most common cancer among young adults and juveniles, causing most of the cancer-related deaths in this age group. The report projects the segment of primary brain tumor to witness an incrementing demand at CAGR of 8.7% during the forecast period from 2017 to 2025.
On the basis of diagnosis type, the global brain tumor diagnosis and treatments market has been bifurcated into CT-Scan, MRI, Molecular Testing, PET-CT Scan, and EEG, with the former accounting for more than 35% share of global market in 2016. It has been noted that CT-Scan remain the most preferred choice of brain cancer diagnosis, owing to their ability to effectively differentiate between bone masses and elaborate soft tissues, besides offering the option to click 3D images in a series at multiple angle. In addition to that, upcoming technological advancements in innovative mobile CT-Scan devices are also expected to aid to the growth of the CT-Scan diagnosis segment during the forecast period. Treatment-wise, surgery category has remained the most preferable primary treatment for brain tumor. It has identified as the first and the only treatment for most type of the brain tumors. That being said, radiation therapy is projected for a strong growth rate during forecast period of 2017 to 2025, a result of growing awareness regarding noninvasive novel treatment due to technological advancements.
Europe Projected for the Best Growth Rate
In 2016, North America accounted for the most prominent share of the demand for brain tumor diagnosis and treatments. The U.S. dominated the brain tumor diagnosis and treatments market in North America, serving about 89.3% share in of North America market in 2016. This dominance is essentially due to the factors such as large number of people diagnosed with brain tumor, extensive research and development activities, technological advancements, and increasing healthcare awareness about the treatment and management of brain tumor are driving market growth. On the other hand, Europe is projected for the best CAGR among all regions during the forecast period, gaining substantial demand from the countries of Germany and The U.K. Rising prevalence of brain tumors disease, escalating percentage of geriatrics among the European population, and government’s initiative regarding growing awareness of advanced technologies are some of the key factors driving the brain tumor diagnosis and treatments market in Europe.
Pfizer, Inc., Toshiba Medical Systems, GE Healthcare, AstraZeneca, Merck & Co., Inc., Siemens Healthineers, Carestream Health, Hitachi Medical Corporation, Philips Healthcare, and Shimadzu Corporation are some of the key companies currently operating in the global brain tumor diagnosis and treatments market.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)